51 results
8-K
EX-1.1
ARCT
Arcturus Therapeutics Holdings Inc
17 Apr 20
Entry into a Material Definitive Agreement
6:06am
a Material Adverse Effect. Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which, if decided adversely … Subsidiaries or any of their properties or assets (“Governmental Authority”) of any inquiry or investigation or other action that would cause the Shares
8-K
EX-1.1
ARCT
Arcturus Therapeutics Holdings Inc
29 Jul 20
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
6:02am
a Material Adverse Effect. Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which, if decided adversely … of its Subsidiaries or any of their properties or assets (“Governmental Authority”) of any inquiry or investigation or other action that would cause
S-4
EX-8.1
ARCT
Arcturus Therapeutics Holdings Inc
15 Mar 19
Registration of securities issued in business combination transactions
9:35pm
below, we have examined and relied upon, without independent investigation or verification, the accuracy and completeness both initially … assumption herein is made and relied upon with your permission and without independent investigation.
In rendering our opinion, we have considered
8-K
EX-1.1
ARCT
Arcturus Therapeutics Holdings Inc
8 Dec 20
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
9:01am
be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which … the Company or any of its Subsidiaries or any of their properties or assets (“Governmental Authority”) of any inquiry or investigation or other action
8-K
EX-10.1
flduud
5 Aug 19
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
9:14am
8-K
EX-10.1
cwy6xvrqi 45e
27 Sep 19
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
4:25pm
8-K
EX-10.1
r5xzg26srwzgf
2 Aug 19
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
4:29pm
8-K
EX-4.1
5ft 9e00jo
20 Jun 19
License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
6:06am
8-K
EX-10.1
m852acgzfzcyp6o
27 Mar 20
Entry into a Material Definitive Agreement
5:20pm
8-K
EX-1.1
49eyyj94
2 Aug 19
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
4:29pm
8-K
EX-1.1
i7b4kb2dvlmxi5u0 rw
27 Sep 19
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
4:25pm
S-4/A
EX-8.2
pnlsw
11 Apr 19
Registration of securities issued in business combination transactions (amended)
5:26pm
8-K
4qii9h1q6m xi1m7
23 Sep 19
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. andRe-Appointment of Andy Sassine to the Board of Directors
4:34pm
8-K
EX-99.1
efwyl0bsc2gf75i8py
23 Sep 19
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. andRe-Appointment of Andy Sassine to the Board of Directors
4:34pm
8-K12B
EX-14.1
8ua3v
14 Jun 19
Notification of registration of securities
5:10pm